IJCS | Volume 31, Nº5, September / October 2018

490 Pivatto Júnior et al. SAMe-TT 2 R 2 score forVTE patients? Int J Cardiovasc Sci. 2018;31(5)483-491 Original Article reference center, add to the existing body of knowledge suggesting that the SAMe-TT 2 R 2 score should not be used in patients with VTE in its present form. To predict response to VKA therapy in patients with VTE, we believe that a new score or a modification of the SAMe-TT 2 R 2 score will be necessary. Author contributions Conception and design of the research: Pivatto Júnior F, Salla RF, Cé LC, Biolo A, Scheffel RS. Acquisition of data: Pivatto Júnior F, Salla RF, Cé LC, Führ B. Analysis and interpretation of the data: Pivatto Júnior F, Salla RF, Cé LC, Biolo A, Silva ALFA, Scheffel RS. Statistical analysis: Pivatto Júnior F. Writing of the manuscript: Pivatto Júnior F, Salla RF, Cé LC, Blaya MB, Scheffel RS. Critical revision of the manuscript for intellectual content: Pivatto Júnior F, Salla RF, Cé LC, Biolo A, Silva ALFA, Führ B, Amon LC, Blaya MB, Scheffel RS. Supervision / as the major investigador: Pivatto Júnior F. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associated with any thesis or dissertation work. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Hospital de Clínicas de Porto Alegre (HCPA) under the protocol number 16-0489. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Free and informed consent was dispensed because of the retrospective nature of data collection. 1. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of andmortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;126(9):832.e13-21. 2. Brasil. Ministério da Saúde. DATASUS. Morbidade hospitalar do SUS (SIH/SUS). [Internet]. [Citado em 2017 nov 10]. Disponível em: http:// tabnet.datasus.gov.br . 3. Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med. 2001;1(1):7-26. 4. Alotaibi GS, Wu C, Senthilselvan A, McMurtry MS. Secular trends in incidence andmortality of acute venous thromboembolism: the AB-VTE Population-Based Study. Am J Med. 2016;129(8):879.e19-25 5. Demelo-Rodríguez P, Postigo-Esteban A, García-Fernández-Bravo I, Agud M, Calpena S, Camacho M, et al. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in a cohort of patients with venous thromboembolism treated with vitamin K antagonists. Thromb Res. 2016 Nov;147:58-60. 6. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT2R2 score. Chest. 2013;144(5):1555-63. 7. Pivatto Júnior F, Scheffel RS, Ries L, Wolkind RR, Marobin R, Barkan SS, et al. SAMe-TT2R2 score in an outpatient anticoagulation clinic for prediction of time in therapeutic range and adverse events. Arq Bras Cardiol. 2017;108(4):290-6. 8. Kataruka A, Kong X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, et al. SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2 experience. Vasc Med. 2017;22(3):197-203. 9. Palareti G, Antonucci E, Lip GY, Testa S, Guazzaloca G, Falanga A, et al. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. Thromb Haemost. 2016;115(6):1101-8. 10. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72. 11. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al; ESCCommittee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-47. Erratum in: Eur Heart J. 2013;34(10):790. Eur Heart J. 2013;34(36):2850-1. 12. PistersR,LaneDA,NieuwlaatR,deVosCB,CrijnsHJ,LipGY.Anoveluser- friendlyscore(HAS-BLED)toassess1-yearriskofmajorbleedinginpatients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100. 13. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16(1):9-13. 14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266. 15. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non- surgical patients. J Thromb Haemost. 2005;3(4):692-4. 16. Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost. 2010;8(1):101-6. 17. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-9. References